RxDoctor Payments Data

Ami Patel, MD

Internal Medicine · Wilmington, NCNPI 1407895907

Payments from drug & device makers

$2,984in general payments, 2019–2025

Across 186 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$666
  • AstraZeneca$482
  • Lilly USA, LLC$319
  • AbbVie$280
  • Intra-sana Laboratories$167
  • Pfizer$157
  • plus $912 from 24 others

What the payments were for

  • Food & beverage$2,95199%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,984 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$50,846
Medicare patients
195
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$77,997
MounjaroTirzepatide67$71,576
JardianceEmpagliflozin21$14,981
EliquisApixaban18$9,562
PremarinEstrogens, Conjugated20$6,779
SynthroidLevothyroxine Sodium28$3,245
Colesevelam Hcl18$2,179
Metoprolol Succinate173$2,099
Levothyroxine Sodium206$2,003
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,954
Olmesartan Medoxomil80$1,772
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid12$1,698
Estradiol24$1,649
Losartan Potassium155$1,463
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide54$1,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$666$77,99769 claims
Lilly USA, LLCMounjaro$319$71,57667 claims
PfizerEliquis, Premarin, Paxlovid$157$17,77049 claims
Boehringer IngelheimJardiance$90$14,98121 claims
AbbVieSynthroid$280$3,24528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →